NIPTIFY - reliable information for a peaceful pregnancy
NIPTIFY is an advanced non-invasive prenatal test (NIPT) that gives parents-to-be early and reliable information about the health of their baby - safely, accurately and without risk to the foetus.
The test is developed and implemented by Celvia CC AS, a leading Estonian biotechnology company specialising in genetic diagnostics. All analyses are carried out in Celvia's high-tech laboratory in Estonia, which operates to the highest European quality standards. Advanced technology, fast and reliable results
NIPTIFY is based on the analysis of freely circulating fetal DNA from a pregnant woman's blood. Using the innovative Focus Plus method and cutting-edge Illumina sequencing technology , the test analyses up to 3.6 times more fetal DNA than conventional NIPT tests.
Results are available within 7-10 working days, starting from the 10th week of pregnancy.
NIPTIFY beats the risk of the most common and clinically important genetic abnormalities, including:
- Down syndrome (trisomy 21)
- Edwards syndrome (trisomy 18)
- Patau syndrome (trisomy 13)
- Turner syndrome (monosomy X)
- DiGeorge syndrome (microdeletion 22q11)
In addition, it allows for extended genomic analysis, including other chromosomal abnormalities, microdeletionsand selected genetic changes.
Why choose NIPTIFY?
- Safe and non-invasive - just one blood draw
- Exceptional accuracy - more than 99% for the most common trisomies
- Fast results - in 7-10 working days
- Extended genetic insight
- Also suitable for IVF and OBMP pregnancies
- Estonian quality - Celvia analysis
NIPTIFY is a screening test, not a diagnostic test, and does not replace ultrasound examinations. But it gives you more clarity, more information and more peace of mind during one of the most beautiful, but also most delicate, times of your life.